Clinical Trial Update: A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating the combination of mavorixafor and ibrutinib in Waldenström macroglobulinemia patients with MYD88 and CXCR4 mutations. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Mavorixafor (mavorixafor)

Snippet

Sponsor: X4 Pharmaceuticals | Conditions: Waldenstrom's Macroglobulinemia | Phase 1 | Status: COMPLETED